OKYO Pharma Limited (OKYO): מכפיל P/S

The absence of predictable cash flows due to research expenditures makes the startup's credit profile dependent on investments. The current price-to-sales ratio on the GURU.Markets chart demonstrates volatility, where describes the current status of the metric. The financial stability of OKYO Pharma Limited (OKYO) relies on the efficacy of the OK-101 molecule in the battle for patents and a reliable system of international cold chain transportation for biomaterials.

Conservative capital demands maximum transparency in business valuation amid high uncertainty. The P/S ratio correlates the market value of OKYO Pharma (OKYO) with actual revenue, determining how much an investor pays per unit of sales. The absence of approved ophthalmological drugs and the risks of trial failures make this calculation critical for analyzing capital stability. The dynamics of these proportions on the P/S chart help determine the degree of asset overheating.